Q2 FY2026 EarningsQ2 FY26 beat revenue consensus but missed on the bottom line due to aggressive strategic investments. Revenue was $189.9M vs. $184.0M expected (+3.2% variance), driven by a 29% surge in Service revenue. However, Adjusted EPS of $0.44 missed the $0.48 consensus by 8.3%, and GAAP Net Income of $14.7M fell short of the $18.1M forecast. Management raised the low end of FY26 revenue guidance to $737M-$757M, reinforcing a growth-first strategy as the company invests in European air logistics through the PAD Aviation acquisition.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: TransMedics(TMDX) the Revenue is 189.95 M (+20.7%), Beat estimate;the EBIT is 23.74 M (-35.09%), Miss estimate;the EPS is 0.41 (-55.43%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.19B20.70%
0.18B16.92%
+0.01B3.78%
EBITMiss expectations
0.02B35.09%
0.03B30.03%
-0.00B5.06%
EPSMiss expectations
0.4155.43%
0.486747.10%
-0.07678.33%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf